Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors

NCT06326411 is registered in ClinicalTrials.gov with Nested Therapeutics, Inc as lead sponsor.

NCT NCT06326411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06326411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors
Lead sponsor
Nested Therapeutics, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
April 9, 2024
Completion date
November 30, 2029
Enrollment
230 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, mapk pathway gene mutation, mek mutation, melanoma, nsclc, oncology, raf gene mutation, ras (kras or nras) gene mutation, solid tumor, adult